Vect-Horus

Vect-Horus appoints Claudia Fromond as new Director of R&D

Emmanuelle BETTENDORF — 2026-03-10T08:10:40Z

We are very pleased to welcome Claudia Fromond to Vect-Horus as our new Director of R&D.

Claudia is a highly regarded pharmacology and translational science leader with extensive experience in R&D. She has successfully overseen first-in-class programs from discovery to Investigational New Drug (IND) application and early clinical development, including a portfolio of seven IND-enabling programs which achieved Phase 1/2 readiness.

“Claudia has a proven track record of successfully managing R&D projects and shaping R&D strategy across numerous modalities. I am confident that her expertise and vision will be key to advancing our technology and expanding our external collaborations,” said Alexandre Tokay, co-founder and CEO of Vect-Horus.

Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals

Emmanuelle BETTENDORF — 2026-02-03T14:28:27Z

We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.

“We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus' leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with Pharma and Biotech companies like OliX,” said Alexandre Tokay, CEO of Vect-Horus.

“This partnership has the potential to accelerate the development of innovative treatments and bring renewed hope to patients worldwide, and we are looking forward to a strong collaboration with OliX.”

https://www.globenewswire.com/news-release/2026/02/03/3230746/0/en/Vect-Horus-Enters-a-CNS-Focused-Research-Collaboration-with-OliX-Pharmaceuticals.html

Meet Vect-Horus at Deeptech in Glioblastoma Symposium

Emmanuelle BETTENDORF — 2026-01-13T09:02:03Z

Cédric Malicet, our Oncology Program Director, will be taking part in a panel discussion at the DeepTech in Glioblastoma conference, organized by Paris Saclay Cancer Cluster (PSCC), and taking place January 22 in Villejuif, France.

Cedric will participate in a pitch session entitled “A comprehensive and diverse front against glioblastoma”, along with representatives from Carthera, TheraSonic, Robeauté, Innov'nCare , with the discussion moderated by Professor Ahmed Idbaih .

It takes place during the first session at 9:30am CET.

We look forward to seeing you there!
👉 https://lnkd.in/dEEE9W4G

Meet Vect-Horus at BIO Japan, October 8-10, 202

Emmanuelle BETTENDORF — 2025-09-19T14:17:17Z

We are excited to be attending BioJapan, taking place October 8-10.
Our Senior Business Developer Faustine Ramel will be in Yokohama for the event – please let us know if you would like to schedule a meeting.
https://jcd-expo.jp/en/

- News / Agenda

How blood–brain barrier technology is unleashing CNS therapies

Emmanuelle BETTENDORF — 2025-09-19T13:52:41Z

Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
It's well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

- News / page_accueil_3_actus, Science

RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for GBM and PDAC

Emmanuelle BETTENDORF — 2025-09-19T13:36:02Z

Together with our partner Radiomedix, Inc. , we have successfully dosed the first patient in an exploratory Investigational New Drug study evaluating the diagnostic 203Pb-RMX-VH-PIB in Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).

“The initiation of this clinical trial is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix,” says Alexandre Tokay, CEO of Vect-Horus.

“We are looking forward to generating clinical data together with RadioMedix with the aim of expanding the therapeutic treatment options available to patients with GBM and PDAC.”

👉 https://www.globenewswire.com/news-...

Our latest research article is now available on bioRxiv and medRxiv

Emmanuelle BETTENDORF — 2025-07-11T09:14:41Z

In this study, we explored the identification and optimization of cross-species reactive VHHs (single-domain antibodies from camelids) targeting the transferrin receptor 1 (TfR1) — a promising strategy for delivering therapeutics across the blood-brain barrier.

We focused on two candidates, C5 and B8, which bind TfR1 in rodents, non-human primates, and humans. These VHHs show potential as molecular shuttles for transporting imaging or therapeutic agents across species — paving the way for smoother translation from preclinical to clinical development.

Read the full article: : Identification and optimization of trans-species reactive TfR1-binding VHH as tools for drug delivery across the blood brain barrier

Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders

Emmanuelle BETTENDORF — 2025-07-11T09:08:57Z

We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!

The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna's proprietary OligoCreator® oligonucleotide discovery platform.

The combination of these two technologies will expand Secarna's targeted delivery portfolio, offering a novel approach that could potentially transform the treatment of neurodegenerative diseases.

“This research collaboration represents a unique opportunity to overcome the long-standing delivery challenges through the blood-brain barrier and bring forward innovative treatment options for patients who today have limited and ineffective treatment option,” says Alexandre Tokay, co-founder and CEO of Vect-Horus.

Click here for the full press release : https://www.globenewswire.com/fr/news-release/2025/07/10/3113000/0/fr/Secarna-Pharmaceuticals-et-Vect-Horus-annoncent-un-programme-de-recherche-pour-le-transport-cibl%C3%A9-des-th%C3%A9rapies-visant-l-ARN-pour-traiter-les-maladies-du-syst%C3%A8me-nerveux-central.html

Vect-Horus appoints Carole Imbert as Chief Financial Officer to further reinforce its executive management team

Emmanuelle BETTENDORF — 2025-03-25T12:37:22Z

We are thrilled to welcome Carole Imbert to our executive management team as our new Chief Financial Officer.

“Her extensive background in financial strategy and investor relations will be complementary to our existing skilled team, and an invaluable asset to drive our growth and secure a strong financial position to underpin development of our vectors that facilitate targeting and delivery of therapeutics,” says @Alexandre Tokay, co-founder and CEO of Vect-Horus.

“Carole's leadership will be crucial in driving our financial strategy forward, based on our proprietary VECTrans® technology both to develop an internal pipeline of products and through partnerships.”

Carole brings a wealth of experience in financial management and structuring. Most recently at Crédit Mutuel Arkéa, she served as Head of Financial and ESG Research for Arkea Investment Services, overseeing the asset management divisions of Schelcher Prince Gestion and Federal Finance Gestion.

Press Release available here

Vect-Horus has been honored with a prestigious European Enterprise Award

Emmanuelle BETTENDORF — 2025-03-18T13:26:21Z

We are thrilled to announce that Vect-Horus has been honored with a prestigious European Enterprise Award by EU Business News! Vect-Horus is cited as one of the Pharma & Biotech Innovators of the Year 2024 ».

These awards recognize outstanding businesses thriving across Europe. This recognition highlights our ongoing commitment to innovation in biotechnology, particularly our efforts to revolutionize drug delivery using our unique VECTrans® technology.

A heartfelt thank you to our dedicated team, partners, and stakeholders for their unwavering support and collaboration. This achievement is a testament to our shared vision and hard work.

We look forward to continuing our journey of innovation and making a meaningful impact on patients' lives across the globe.

👉 https://lnkd.in/dbSnu6P8